BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37516450)

  • 1. Pseudomonas aeruginosa is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics.
    Martin LW; Gray AR; Brockway B; Lamont IL
    FEMS Microbiol Lett; 2023 Jan; 370():. PubMed ID: 37516450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
    Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G; Gilpin DF; Schneiders T; Hoffman LR; McKevitt M; Elborn JS; Tunney MM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
    Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
    J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration.
    Alvarez-Ortega C; Harwood CS
    Mol Microbiol; 2007 Jul; 65(1):153-65. PubMed ID: 17581126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
    Jabalameli F; Emaneini M; Beigverdi R; Halimi S; Siroosi M
    Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):61. PubMed ID: 37475017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Antibiotics against Pseudomonas aeruginosa in an
    Diaz Iglesias Y; Van Bambeke F
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
    [No Abstract]   [Full Text] [Related]  

  • 13. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum.
    Palmer KL; Brown SA; Whiteley M
    J Bacteriol; 2007 Jun; 189(12):4449-55. PubMed ID: 17400735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
    Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
    J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calprotectin-Mediated Zinc Chelation Inhibits Pseudomonas aeruginosa Protease Activity in Cystic Fibrosis Sputum.
    Vermilyea DM; Crocker AW; Gifford AH; Hogan DA
    J Bacteriol; 2021 Jun; 203(13):e0010021. PubMed ID: 33927050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
    Kolpen M; Kühl M; Bjarnsholt T; Moser C; Hansen CR; Liengaard L; Kharazmi A; Pressler T; Høiby N; Jensen PØ
    PLoS One; 2014; 9(1):e84353. PubMed ID: 24465406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.